Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J.

Nat Commun. 2019 Feb 20;10(1):932. doi: 10.1038/s41467-019-08956-x.

2.

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J.

Nat Commun. 2019 Feb 6;10(1):620. doi: 10.1038/s41467-019-08541-2. Erratum in: Nat Commun. 2019 Feb 20;10(1):932.

3.

Immune cell phenotype and functional defects in Netherton syndrome.

Eränkö E, Ilander M, Tuomiranta M, Mäkitie A, Lassila T, Kreutzman A, Klemetti P, Mustjoki S, Hannula-Jouppi K, Ranki A.

Orphanet J Rare Dis. 2018 Nov 26;13(1):213. doi: 10.1186/s13023-018-0956-6.

4.

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Lissina A, McLaren JE, Ilander M, Andersson EI, Lewis CS, Clement M, Herman A, Ladell K, Llewellyn-Lacey S, Miners KL, Gostick E, Melenhorst JJ, Barrett AJ, Price DA, Mustjoki S, Wooldridge L.

Sci Rep. 2018 Feb 7;8(1):2534. doi: 10.1038/s41598-017-18062-x.

5.

ADA2 deficiency: Clonal lymphoproliferation in a subset of patients.

Trotta L, Martelius T, Siitonen T, Hautala T, Hämäläinen S, Juntti H, Taskinen M, Ilander M, Andersson EI, Zavialov A, Kaustio M, Keski-Filppula R, Hershfield M, Mustjoki S, Tapiainen T, Seppänen M, Saarela J.

J Allergy Clin Immunol. 2018 Apr;141(4):1534-1537.e8. doi: 10.1016/j.jaci.2018.01.012. Epub 2018 Jan 31. No abstract available.

PMID:
29391253
6.

Immune control in chronic myeloid leukemia.

Ilander M, Mustjoki S.

Oncotarget. 2017 Nov 3;8(61):102763-102764. doi: 10.18632/oncotarget.22279. eCollection 2017 Nov 28. No abstract available.

7.

Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner.

Kreutzman A, Colom-Fernández B, Jiménez AM, Ilander M, Cuesta-Mateos C, Pérez-García Y, Arévalo CD, Brück O, Hakanen H, Saarela J, Ortega-Carrión A, de Rosendo A, Juanes-García A, Steegmann JL, Mustjoki S, Vicente-Manzanares M, Muñoz-Calleja C.

Clin Cancer Res. 2017 Nov 1;23(21):6697-6707. doi: 10.1158/1078-0432.CCR-16-0667. Epub 2017 Aug 18.

8.

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.

Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A, Kovanen PE, Porkka K, Lee FY, Mustjoki S.

Cancer Immunol Res. 2017 Feb;5(2):157-169. doi: 10.1158/2326-6066.CIR-16-0061-T. Epub 2017 Jan 10.

9.

Combined immunodeficiency and hypoglycemia associated with mutations in hypoxia upregulated 1.

Haapaniemi EM, Fogarty CL, Keskitalo S, Katayama S, Vihinen H, Ilander M, Mustjoki S, Krjutškov K, Lehto M, Hautala T, Eriksson O, Jokitalo E, Velagapudi V, Varjosalo M, Seppänen M, Kere J.

J Allergy Clin Immunol. 2017 Apr;139(4):1391-1393.e11. doi: 10.1016/j.jaci.2016.09.050. Epub 2016 Nov 29. No abstract available.

10.

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S.

Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28.

11.

Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation.

Hannula-Jouppi K, Laasanen SL, Ilander M, Furio L, Tuomiranta M, Marttila R, Jeskanen L, Häyry V, Kanerva M, Kivirikko S, Tuomi ML, Heikkilä H, Mustjoki S, Hovnanian A, Ranki A.

JAMA Dermatol. 2016 Apr;152(4):435-42. doi: 10.1001/jamadermatol.2015.5827.

PMID:
26865388
12.

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells.

Kreutzman A, Ilander M, Porkka K, Vakkila J, Mustjoki S.

Oncoimmunology. 2014 May 29;3:e28925. eCollection 2014.

13.

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia.

Ilander M, Kreutzman A, Mustjoki S.

Oncoimmunology. 2014 Apr 29;3:e28781. eCollection 2014.

14.

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.

Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, Vakkila J, Mustjoki S.

PLoS One. 2014 Jan 31;9(1):e87794. doi: 10.1371/journal.pone.0087794. eCollection 2014.

15.

Immunology and immunotherapy of chronic myeloid leukemia.

Ilander M, Hekim C, Mustjoki S.

Curr Hematol Malig Rep. 2014 Mar;9(1):17-23. doi: 10.1007/s11899-013-0190-1. Review.

PMID:
24390549
16.

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.

Ilander M, Koskenvesa P, Hernesniemi S, Lion T, Porkka K, Mustjoki S.

Leuk Lymphoma. 2014 Apr;55(4):934-7. doi: 10.3109/10428194.2013.812788. Epub 2013 Jul 25. No abstract available.

PMID:
23777365
17.

Intracerebral Borna disease virus infection of bank voles leading to peripheral spread and reverse transcription of viral RNA.

Kinnunen PM, Inkeroinen H, Ilander M, Kallio ER, Heikkilä HP, Koskela E, Mappes T, Palva A, Vaheri A, Kipar A, Vapalahti O.

PLoS One. 2011;6(8):e23622. doi: 10.1371/journal.pone.0023622. Epub 2011 Aug 22.

Supplemental Content

Loading ...
Support Center